Literature DB >> 1833315

Activation of human natural killer cells by lipopolysaccharide and generation of interleukin-1 alpha, beta, tumour necrosis factor and interleukin-6. Effect of IL-1 receptor antagonist.

P Conti1, R A Dempsey, M Reale, R C Barbacane, M R Panara, M Bongrazio, J W Mier.   

Abstract

The presence in the body of an antigen species or a bacterial lipopolysaccharide (LPS) has a pleiotropic effect on the immune system activating macrophages, lymphocytes and natural killer (NK) cells. Recently it has been reported that human macrophages not only secrete interleukin-1 (IL-1) but also its inhibitor, called IL-1 receptor antagonist (IL-1ra), structurally similar to IL-1 beta, but with no IL-1-like activity and which binds to the IL-1 receptor. In this study we show that LPS stimulates NK cell activity and IL-1ra potentiates the stimulatory effect of human recombinant interleukin-2 (hrIL-2) on NK cell activity. In addition, we found that hrIL-1ra inhibits DNA synthesis in lymphocyte culture stimulated with phytohaemagglutinin (PHA) (20 micrograms/ml), presumably via IL-1 inhibition. We also found that LPS is a potent stimulator of monokines: IL-6, tumour necrosis factor-alpha (TNF-alpha), and IL-1 beta, as determined by radioimmunoassay method, and interferon-gamma (IFN-gamma), IL-2, TNF-alpha and IL-1 alpha, as determined by ELISA method, in peripheral blood mononuclear cells (PBMC). We used PBMC as effector cells since LPS requires the presence of accessory cells to activate lymphocytes and bind to the HLA-DR molecule on accessory cells. The effect of LPS on PBMC cytotoxicity has been compared with an endotoxin-free extract of Escherichia coli, OM-8990, which did not provoke cytokine production nor did it cause enhancement of NK cell activity. We found that human recombinant IL-1ra potentiates the stimulatory effect of IL-2 on NK cell activity, similar to hrIL-1 beta. The potentiation of IL-2 in stimulating NK cell activity by IL-1ra is not yet understood. Since IL-1ra is a part of the IL-1 family, it may work in a similar fashion to IL-1, which also potentiates IL-2 to enhance NK cell activity but has been shown not to be directly important in tumour cell killing. In addition, hrIL-1ra can amplify the effect of IL-2 on NK activity, possibly by inhibiting the cyclo-oxygenase products, which are immunosuppressive and are generated in antigen-stimulated PBMC cultures. The generation of IFN-gamma by PBMC after treatment with LPS strongly suggests that the enhancement of NK cell activity may be indirectly due to IFN production.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1833315      PMCID: PMC1384575     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  40 in total

1.  Interleukin 1 and tumor necrosis factor: studies on the induction by lipopolysaccharide partial structures.

Authors:  H D Flad; H Loppnow; W Feist; M H Wang; H Brade; S Kusumoto; E T Rietschel; A J Ulmer
Journal:  Lymphokine Res       Date:  1989

Review 2.  Immunoadjuvants and analogs of immunomodulatory bacterial structures.

Authors:  L D Lise; F Audibert
Journal:  Curr Opin Immunol       Date:  1989-12       Impact factor: 7.486

3.  rIL 2-induced proliferation of human circulating NK cells and T lymphocytes: synergistic effects of IL 1 and IL 2.

Authors:  M H Ben Aribia; E Leroy; O Lantz; D Métivier; B Autran; B Charpentier; T Hercend; A Senik
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

4.  Monocyte interleukin 2 receptor gene expression and interleukin 2 augmentation of microbicidal activity.

Authors:  S M Wahl; N McCartney-Francis; D A Hunt; P D Smith; L M Wahl; I M Katona
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

5.  Interferons as inhibitors of interleukin 1 induced interleukin 1 synthesis.

Authors:  R Schindler; P Ghezzi; C A Dinarello
Journal:  Lymphokine Res       Date:  1989

6.  Activation of human natural killer cells by lipopolysaccharide from Actinobacillus actinomycetemcomitans.

Authors:  R A Lindemann; F Eilber
Journal:  Arch Oral Biol       Date:  1989       Impact factor: 2.633

7.  Bacterial induction of human activated lymphocyte killing and its inhibition by lipopolysaccharide (LPS).

Authors:  J Tarkkanen; H Saxén; M Nurminen; P H Mäkelä; E Saksela
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

8.  Immunoregulation and immunostimulation of murine lymphocytes by recombinant human interleukin-2.

Authors:  J E Talmadge
Journal:  J Biol Response Mod       Date:  1985-02

9.  Restoration of anti-interleukin-1 depressed natural killer activity by human recombinant interferon alpha or gamma, human recombinant interleukin-2 and indomethacin.

Authors:  P Conti; M Reale; P U Angeletti; C A Dinarello
Journal:  Int J Immunopharmacol       Date:  1988

10.  Natural killer cell activation and interferon production by peripheral blood lymphocytes after exposure to bacteria.

Authors:  G R Klimpel; D W Niesel; M Asuncion; K D Klimpel
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

View more
  17 in total

1.  MUC16 suppresses human and murine innate immune responses.

Authors:  Mildred Felder; Arvinder Kapur; Alexander L Rakhmilevich; Xiaoyi Qu; Paul M Sondel; Stephen D Gillies; Joseph Connor; Manish S Patankar
Journal:  Gynecol Oncol       Date:  2019-01-06       Impact factor: 5.482

2.  Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination.

Authors:  David Pejoski; Casimir de Rham; Paola Martinez-Murillo; Francesco Santoro; Floriane Auderset; Donata Medaglini; Gianni Pozzi; Maria Vono; Paul-Henri Lambert; Angela Huttner; Mariëlle C Haks; Tom H M Ottenhoff; Jean Villard; Claire-Anne Siegrist
Journal:  NPJ Vaccines       Date:  2020-04-14       Impact factor: 7.344

3.  Immunomodulatory potential of nanocurcumin-based formulation.

Authors:  Mahendra Kumar Trivedi; Sambhu Charan Mondal; Mayank Gangwar; Snehasis Jana
Journal:  Inflammopharmacology       Date:  2017-09-18       Impact factor: 4.473

Review 4.  Modulation of Toll-like receptor signaling in innate immunity by natural products.

Authors:  Luxi Chen; Jianhua Yu
Journal:  Int Immunopharmacol       Date:  2016-02-15       Impact factor: 4.932

5.  Augmentation of monocyte chemotactic protein-1 and mRNA transcript in chronic inflammatory states induced by potassium permanganate (KMnO4) in vivo.

Authors:  P Conti; M Reale; C Feliciani; S Frydas; M Trakatellis; F C Placido; I Cataldo; M Di Gioacchino; R C Barbacane
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

6.  Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects.

Authors:  D Yang; M Satoh; H Ueda; S Tsukagoshi; M Yamazaki
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

7.  4-Deoxypyridoxine inhibits chronic granuloma formation induced by potassium permanganate in vivo.

Authors:  S Fridas; A Trakatellis; E Karagouni; E Dotsika; C Himonas; P Conti
Journal:  Mol Cell Biochem       Date:  1994-07-13       Impact factor: 3.396

8.  Inhibition of interleukin-1 beta mRNA expression and interleukin-1 alpha and beta secretion by a specific human recombinant interleukin-1 receptor antagonist in human peripheral blood mononuclear cells.

Authors:  P Conti; C Feliciani; R C Barbacane; M R Panara; M Reale; F C Placido; D N Sauder; R A Dempsey; P Amerio
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

9.  Interleukin-1 receptor antagonist inhibits calcium accumulation in in vivo chronic granuloma induced by potassium permanganate.

Authors:  P Conti; M Reale; M R Panara; S Fridas; F C Placido; R C Barbacane
Journal:  Calcif Tissue Int       Date:  1993-04       Impact factor: 4.333

10.  MicroRNA 223 3p Negatively Regulates the NLRP3 Inflammasome in Acute and Chronic Liver Injury.

Authors:  Carolina Jimenez Calvente; Hana Del Pilar; Masahiko Tameda; Casey D Johnson; Ariel E Feldstein
Journal:  Mol Ther       Date:  2019-09-13       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.